Metabolic factors affecting response to adjuvant anti-PD1 therapy for melanoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination ...
Serial CTRS was developed from routine-care CTs and externally validated across 10 institutions and the phase 1 GARNET trial, covering ICI monotherapy and combinations across all lines. Multivariable ...
image: 68Ga-ABY-025 PET/CT and 18F-FDG PET/CT images at baseline with 18F-FDG PET/CT follow-up after 2 cycles of treatment in biopsy-confirmed HER2-positive disease. (A) Patient with high 68Ga-ABY-025 ...
Distinct margin mutation dissemination patterns in EGFR L858R-mutated lung cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...
A new imaging agent, 68 Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results